NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Wuhan Wansheng Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
+11 more ↓
66%
Finnrick rating
#369 of 500 ranked vendors
184 of 267 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Wuhan Wansheng Biotechnology's strongest purity-focus evidence sits in high-volume Retatrutide, Tirzepatide, and GHK-Cu, but the catalog is uneven rather than uniformly clean. Tesamorelin, BPC-157, and CJC-1295 carry repeated purity, identity, or fill failures; the record is recent and broad, with mixed trajectory and recurring batch-ID gaps.

methodology →
vendor intelligence report
Vendor Intelligence Report: Wuhan Wansheng Biotechnology

Infrastructure mapping follows WWB lookalike storefronts into fake lab and review pages, including a Gemma Conway Telegram route on a promoted .co storefront. The full report checks the Chinese registry trail, vendor-hosted Janoshik links and Trustpilot-style review layer.

41 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.08
90%
23
2
Retatrutide
$0.85
85%
80
3
Tirzepatide
$0.61
84%
54
4
Semaglutide
$0.38
65%
5
5
Ipamorelin
$0.60
65%
15
6
Melanotan II
$0.45
64%
6
7
PT-141
-
62%
4
8
Cagrilintide
$2.20
54%
15
9
TB-500
$0.51
44%
11
10
BPC-157
$0.55
43%
20
11
Tesamorelin
$1.75
32%
27
12
CJC-1295
$2.60
29%
7
13
5-Amino-1MQ
$0.15
-
0
14
Epithalon
$0.60
-
0
15
KPV
$1.10
-
0
16
Mazdutide
$1.85
-
0
17
Sermorelin
$1.50
-
0
18
Survodutide
$2.10
-
0
19
Testosterone
$0.07
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%6 May 2026: 65%6 May 2026: 65%8 May 2026: 65%13 May 2026: 65%18 May 2026: 65%25 May 2026: 65%12 Jun 2026: 65%12 Jun 2026: 65%12 Jun 2026: 65%12 Jun 2026: 65%22 Jun 2026: 66%22 Jun 2026: 66%23 Jun 2026: 66%23 Jun 2026: 66%24 Jun 2026: 66%26 Jun 2026: 66%1 Jul 2026: 66%1 Jul 2026: 66%17 Jul 2026: 66%17 Jul 2026: 66%22 Jul 2026: 66%2 Aug 2026: 66%13 Aug 2026: 66%13 Aug 2026: 66%4 Sep 2026: 66%4 Sep 2026: 67%4 Sep 2026: 66%5 Sep 2026: 66%16 Sep 2026: 66%16 Sep 2026: 66%18 Sep 2026: 66%18 Sep 2026: 66%24 Sep 2026: 66%24 Sep 2026: 66%8 Oct 2026: 66%12 Oct 2026: 66%30 Oct 2026: 66%2 Nov 2026: 65%2 Nov 2026: 65%5 Nov 2026: 65%17 Nov 2026: current 66%65%66%66%May 26Nov 26
Peptide testing

Ordered peptides from Wuhan Wansheng Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
Wuhan Wansheng Biotechnology test history
COA-backed lab tests
1-10 of 200

About Wuhan Wansheng Biotechnology test results from Finnrick

Wuhan Wansheng Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 267 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Wuhan Wansheng Biotechnology peptides in this dataset are BPC-157 (20 tests), Cagrilintide (15 tests) and CJC-1295 (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests. It also includes 1 correction related to this vendor.

Corrections
2025-11-05
Lab correction
These were remade and reanalyzed by Lab G. They traced the discrepancy to a likely human error during preparation.
Peptide testing

Ordered peptides from Wuhan Wansheng Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply